This report was recently updated on November 16 2024 with the latest and most recent
market numbers
Global Inhalable Drugs Market Size, Trends & Analysis - Forecasts to 2026 By Product (Aerosol, Dry Powder Formulation, Spray), By Application (Respiratory, Non – Respiratory Diseases), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis
Inhalable medicines are used for severe lung diseases. They help to regain the normal working of respiratory and pulmonary organs. In this, medicine is directly inhaled through the nose, reaches the airways, and relaxes the swollen bronchial tubes in case of mild or acute bronchitis. This is helpful in efficiently reaching the airways as it doesn’t reach the bloodstreams. The sole reason for the usage of inhalable drugs is to reduce the inflammation in the lungs without oral medicines and soothe the inner part of the lungs from all types of pains and inflammations, as a result, the chances of getting asthma reduces in asthmatic patients. Inhalable drugs reduce the patient’s number of visits to hospitals. They are generally in the form of steroids and anti-inflammatory drugs.
For asthmatic patients, the drugs used are called steroids or corticosteroids, leukotriene modifiers, anticholinergics, and immunomodulators. Following are the inhalable drugs that give better results in controlling asthma: Beclomethasone dipropionate, Budesonide, Fluticasone, Fluticasone, Mometasone, and Mometasone.The most common types of machines used for inhalable drugs are Dry Powder Inhalers, Nebulizers, and Soft Mist inhalers.
The cost of a basic inhalable drug ranges from USD 300 to USD 500 with the generic one costing somewhere around USD 100. The number one producer of inhalable drugs is AstraZeneca, a British-Sweden pharmaceutical and biotechnological company with a net worth of USD 137 Billion.
The factors driving the inhalable drugs market are: Increase in the pollution level across the globe thereby increasing the respiratory diseases among people.The increasing number of tobacco consumption in the form of smoking among people leads to chronic and acute bronchitis, other pulmonary disorders.Presence of asthma in children making it the most chronic disease for children in the world.Enhanced research by biotechnological and pharmaceutical companies for producing better, efficient, and cheaper drugs.
Inhalable drug advancements are expected to drive market growth. Surfactant carriers, nanocrystals, and micro and nanoparticles are used in advanced inhalation therapy. As a result, studies on small molecules are being performed to create novel inhalable drugs. These advances in inhalation therapies include improved systemic availability of medications as well as convenience over invasive approaches.
Based on product,the inhalable drugs market can be segregated intoaerosol, dry powder formulation, and spray.Dry Powder formulation has the highest usage in the market as it is much more efficient and takes comparatively less time to show results, than the other forms of product.Furthermore, the inclusion of a diverse product portfolio and a robust pipeline for this formulation are factors contributing to its dominant market share.Aerosols are expected to rise steadily over the forecast period due to their user-friendliness. Players are constantly searching for ways to create inhalable products that are convenient to use and safe without being too complicated.
Based on application, the inhalable drugs market can be segregated intorespiratory and non-respiratory diseases. Inhalable drugs are mostly used for respiratory and other pulmonary diseases hence, it has the highest usage for respiratory applications in home-care settings. Inhalable medications are often used to treat chronic respiratory disorders like asthma, and COPD, others, as well as non-respiratory diseases like diabetes and Parkinson's disease.Inhaled corticosteroids, which are widely used in the treatment of COPD and asthma due to their efficacy, ability to minimize lung inflammation, and lower need for hospitalization.
North America is dominating this market owing to the highest number of respiratory and pulmonary diseases in the region, the presence of the best inhalable drug manufacturers in the market, the highest number of researches in the region by pharmaceutical and biotechnological companies, government initiatives so that treatment can be made available for everyone, and the best healthcare system across the globe. The Asia Pacific is the fastest-growing market in the forecast timeframe owing to the growing number of respiratory diseases in the young as well geriatric population, increasing number of smokers, and increasing cases of asthma among newborn children.
Sunovion Pharmaceuticals Inc. (SUMITOMO DAINIPPON PHARMA), AstraZeneca, Sanofi, Vectura, Mylan, GlaxoSmithKline, Mundipharma, Boehringer Ingelheim International GmbH, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, and Cipla Inc. among others are the top players inthe inhalable drugs market.
Please note: This is not an exhaustive list of companies profiled in the report.
In March 2021, Pfizer Inc. and the Sanofi-Aventis Group recently announced that the US Food and Drug Administration (FDA) has approved Exuberafor a new drug application (inhaled human insulin powder)
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview and Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 ReportOutlook
2.1 Global Inhalable DrugsMarket Overview, 2019-2026
2.1.1 IndustryOverview
2.1.2 ProductOverview
2.1.3 ApplicationOverview
2.1.4 Regional Overview
Chapter 3 Inhalable Drugs MarketTrends
3.1 MarketSegmentation
3.2 Industry Background, 2019-2026
3.3 MarketKey Trends
3.3.1 Positive Trends
3.3.1.1 Presence of Asthma in children making it the most
chronic diseases for children in the world.
3.3.1.2 Improving healthcare infrastructure
3.3.2 Industry Challenges
3.3.2.1 Side effects of the drugs
3.4 Prospective Growth Scenario
3.4.1 Product
3.4.2 Application
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Technology Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Global Inhalable Drugs Market, By Product
4.1 Product Outlook
4.2 Aerosol
4.2.1 Market Size, By Region, 2019-2026 (USD Billion)
4.3 Dry Powder Formulation
4.3.1 Market Size, By Region, 2019-2026 (USD Billion)
4.4 Spray
4.4.1 Market Size, By Region, 2019-2026 (USD Billion)
Chapter 5 Global Inhalable Drugs Market, By Application
5.1 Application Outlook
5.2 Respiratory
5.2.1 Market Size, By Region, 2019-2026 (USD Billion)
5.3 Non – Respiratory Diseases
5.3.1 Market Size, By Region, 2019-2026 (USD Billion)
Chapter 6Global Inhalable Drugs Market, By Region
6.1 Regional outlook
6.2 North America
6.2.1 Market Size, By Country 2019-2026 (USD Billion)
6.2.2 Market Size, By Product, 2019-2026 (USD Billion)
6.2.3 Market Size, By Type, 2019-2026 (USD Billion)
6.2.4 U.S.
6.2.4.1 Market Size, By Product, 2019-2026 (USD Billion)
6.2.4.2 Market Size, By Type, 2019-2026 (USD Billion)
6.2.5 Canada
6.2.5.1 Market Size, By Product, 2019-2026 (USD Billion)
6.2.5.2 Market Size, By Type, 2019-2026 (USD Billion)
6.3 Europe
6.3.1 Market Size, By Country 2019-2026 (USD Billion)
6.3.2 Market Size, By Product, 2019-2026 (USD Billion)
6.3.3 Market Size, By Type, 2019-2026 (USD Billion)
6.3.4 Germany
6.3.4.1 Market Size, By Product, 2019-2026 (USD Billion)
6.3.4.2 Market Size, By Type, 2019-2026 (USD Billion)
6.3.5 UK
6.3.5.1 Market Size, By Product, 2019-2026 (USD Billion)
6.3.5.2 Market Size, By Type, 2019-2026 (USD Billion)
6.3.6 France
6.3.6.1 Market Size, By Product, 2019-2026 (USD Billion)
6.3.6.2 Market Size, By Type, 2019-2026 (USD Billion)
6.3.7 Italy
6.3.7.1 Market Size, By Product, 2019-2026 (USD Billion)
6.3.7.2 Market Size, By Type, 2019-2026 (USD Billion)
6.3.8 Spain
6.3.8.1 Market Size, By Product, 2019-2026 (USD Billion)
6.3.8.2 Market Size, By Type, 2019-2026 (USD Billion)
6.3.9 Russia
6.3.9.1 Market Size, By Product, 2019-2026 (USD Billion)
6.3.9.2 Market Size, By Type, 2019-2026 (USD Billion)
6.4 Asia Pacific
6.4.1 Market Size, By Country 2019-2026 (USD Billion)
6.4.2 Market Size, By Product, 2019-2026 (USD Billion)
6.4.3 Market Size, By Type, 2019-2026 (USD Billion)
6.4.4 China
6.4.4.1 Market Size, By Product, 2019-2026 (USD Billion)
6.4.4.2 Market Size, By Type, 2019-2026 (USD Billion)
6.4.5 India
6.4.5.1 Market Size, By Product, 2019-2026 (USD Billion)
6.4.5.2 Market Size, By Type, 2019-2026 (USD Billion)
6.4.6 Japan
6.4.6.1 Market Size, By Product, 2019-2026 (USD Billion)
6.4.6.2 Market Size, By Type, 2019-2026 (USD Billion)
6.4.7 Australia
6.4.7.1 Market Size, By Product, 2019-2026 (USD Billion)
6.4.7.2 Market size, By Type, 2019-2026 (USD Billion)
6.4.8 South Korea
6.4.8.1 Market Size, By Product, 2019-2026 (USD Billion)
6.4.8.2 Market Size, By Type, 2019-2026 (USD Billion)
6.5 Latin America
6.5.1 Market Size, By Country 2019-2026 (USD Billion)
6.5.2 Market Size, By Product, 2019-2026 (USD Billion)
6.5.3 Market Size, By Type, 2019-2026 (USD Billion)
6.5.4 Brazil
6.5.4.1 Market Size, By Product, 2019-2026 (USD Billion)
6.5.4.2 Market Size, By Type, 2019-2026 (USD Billion)
6.5.5 Mexico
6.5.5.1 Market Size, By Product, 2019-2026 (USD Billion)
6.5.5.2 Market Size, By Type, 2019-2026 (USD Billion)
6.5.6 Argentina
6.5.6.1 Market Size, By Product, 2019-2026 (USD Billion)
6.5.6.2 Market Size, By Type, 2019-2026 (USD Billion)
6.6 MEA
6.6.1 Market Size, By Country 2019-2026 (USD Billion)
6.6.2 Market Size, By Product, 2019-2026 (USD Billion)
6.6.3 Market Size, By Type, 2019-2026 (USD Billion)
6.6.4 Saudi Arabia
6.6.4.1 Market Size, By Product, 2019-2026 (USD Billion)
6.6.4.2 Market Size, By Type, 2019-2026 (USD Billion)
6.6.5 UAE
6.6.5.1 Market Size, By Product, 2019-2026 (USD Billion)
6.6.5.2 Market Size, By Type, 2019-2026 (USD Billion)
6.6.6 South Africa
6.6.6.1 Market Size, By Product, 2019-2026 (USD Billion)
6.6.6.2 Market Size, By Type, 2019-2026 (USD Billion)
Chapter 7 CompanyLandscape
7.1 Competitive Analysis, 2020
7.2 AstraZeneca
7.2.1 CompanyOverview
7.2.2 Financial Analysis
7.2.3 Strategic Positioning
7.2.4 Info Graphic Analysis
7.3 Sanofi
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Strategic Positioning
7.3.4 Info Graphic Analysis
7.4 Vectura
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Strategic Positioning
7.4.4 Info Graphic Analysis
7.5 Mylan
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Strategic Positioning
7.5.4 Info Graphic Analysis
7.6 GlaxoSmithKline.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Strategic Positioning
7.6.4 Info Graphic Analysis
7.7 Mundipharma
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Strategic Positioning
7.7.4 Info Graphic Analysis
7.8 Boehringer Ingelheim International GmbH
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Strategic Positioning
7.8.4 Info Graphic Analysis
7.9 Cipla Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Strategic Positioning
7.9.4 Info Graphic Analysis
7.10 Merck
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Strategic Positioning
7.10.4 Info Graphic Analysis
7.11 Other Companies
7.11.1 Company Overview
7.11.2 Financial Analysis
7.11.3 Strategic Positioning
7.11.4 Info Graphic Analysis
The Global Inhalable Drugs Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Inhalable Drugs Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
